Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiovascular disease

PCSK9 inhibition: a new player in cholesterol-lowering therapies?

Nature Reviews Nephrology volume 13, pages 450–451 (2017)Cite this article

Subjects

The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489–1499 (2015).

    Article  CAS  Google Scholar 

  2. Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500–1509 (2015).

    Article  CAS  Google Scholar 

  3. Sabatine, M. S. et al. Rationale and design of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk trial. Am. Heart J. 173, 94–101 (2016).

    Article  CAS  Google Scholar 

  4. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).

    Article  CAS  Google Scholar 

  5. Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278 (2005).

    Article  CAS  Google Scholar 

  6. Cholesterol Treatment Trialists Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).

  7. Schmidt, A. F. et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 4, CD011748 (2017).

    PubMed  Google Scholar 

  8. McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015–2021 (2004).

    Article  CAS  Google Scholar 

  9. Ridker, P. M. et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med. 376, 1527–1539 (2017).

    Article  CAS  Google Scholar 

  10. Schwartz, G. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am. Heart J. 168, 682–689 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Population Health, Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK

    David Preiss & Colin Baigent

Authors
  1. David Preiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin Baigent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Preiss.

Ethics declarations

Competing interests

D.P. consulted for Sanofi on three occasions in 2013–2014 during previous employment. C.B is a member of the independent data and safety monitoring board for trials of evolocumab, of which FOURIER was one.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Preiss, D., Baigent, C. PCSK9 inhibition: a new player in cholesterol-lowering therapies?. Nat Rev Nephrol 13, 450–451 (2017). https://doi.org/10.1038/nrneph.2017.94

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2017.94

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing